Tuesday, 16 August 2011

AVI BioPharma - News Release

AVI BioPharma - News Release: "AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced that it has initiated dosing in a Phase 2 study of eteplirsen, the Company's lead exon-skipping therapeutic candidate for the treatment of Duchenne muscular dystrophy (DMD)"

Wednesday, 3 August 2011

Heart Failure Drugs Preserve Muscle in Muscular Dystrophy

Heart Failure Drugs Preserve Muscle in Muscular Dystrophy: "COLUMBUS, Ohio – Two common drugs used to treat heart failure might also improve heart and muscle function in Duchenne muscular dystrophy (DMD), according to a new study. "

Researchers discover biological mechanism behind sarcopenia

Researchers discover biological mechanism behind sarcopenia: "Researchers at Columbia University Medical Center have discovered the biological mechanism behind age-related loss of muscle strength and identified a drug that may help reverse this process."

Monday, 25 July 2011

BBC News - Molecular scalpel hope for Duchenne muscular dystrophy

BBC News - Molecular scalpel hope for Duchenne muscular dystrophy: "A 'molecular scalpel' shows promise in patients with a deadly muscle wasting condition, according to researchers."

AVI BioPharma - News Release

AVI BioPharma - News Release: "The Lancet Publishes Clinical Trial Data That Demonstrate Statistically Significant and Dose-Dependent Expression of Dystrophin in Duchenne Muscular Dystrophy Patients Treated With AVI BioPharma's Eteplirsen"

Friday, 22 July 2011

Coach to Cure MD Set for September 24 Games - AFCA.com—Official Site of the American Football Coaches Association

Coach to Cure MD Set for September 24 Games - AFCA.com—Official Site of the American Football Coaches Association: "For the fourth year in a row, college football coaches nationwide will join together in support of the Coach to Cure MD program, which will be held during games of Saturday, September 24, 2011. The rapidly growing annual effort has raised nearly a million dollars to battle Duchenne muscular dystrophy, and should easily top the million-dollar plateau in 2011."